肝内胆管癌分子靶向治疗的研究进展

肝内胆管癌分子靶向治疗的研究进展摘要：AdvancesinmoleculartargetedtherapyforintrahepaticAbstractIntrahepaticcholangiocarcinoma(Intrahepaticbileductcancer,ICC)isthesecondmostcommonprimarylivercancerafterhepatocellularcarcinoma.Inrecentyears,theincidenceofintrahepaticcholangiocarcinomahasdramatically,andsurgicalresectionistheonlytreatmentforintrahepaticcholangiocarcinoma.However,duetothehighincidenceofmalignanttransformationandthelackofeffectiveearlyscreeningtools,mostpatientsarealreadyinthemiddletolatestagewhendiagnosedandcannotundergoradicalsurgery,resultinginpooroverallsurvivalandprognosis.Foradvancedpatientswhocannotundergosurgicalresection,the5-yearsurvivalrateisonly5%-10%,soadjuvanttherapyiscrucialtoimprovethesurvivalrateofadvancedpatients.Moleculartargetedtherapyisthelatesttrendinthetreatmentofadvancedtumorsandhasshowngoodclinicalresults.Inthefollowing,wewillintroducetheresearchprogressofmoleculartargetedtherapyinICC.Keywords：Intrahepaticcholangiocarcinoma;targetedtherapy;drugs;引言正文肝内胆管癌的发病原因肝内胆管癌的靶向治疗药物HSP90血管内皮生长因子（VEGF）VEGF受体（VEGFR） MAPKMAPK图SEQ图\*ARABIC1异柠檬酸脱氢酶（IsocitrateDehydrogenase,IDH）卡培他滨免疫疗法与靶向治疗的关系新兴靶向治疗策略 总结与展望 WangX,YangX,WangJ,DongC,DingJ,WuM,WangY,DingH,ZhangH,SangX,ZhaoH,HuoL.MetabolicTumorVolumeMeasuredby18F-FDGPET/CTisAssociatedwiththeSurvivalofUnresectableHepatocellularCarcinomaTreatedwithPD-1/PD-L1InhibitorsPlusMolecularTargetedAgents.JHepatocellCarcinoma.2023;10:587-598LAMBERTID,CRISTINZIANOG,PORRUM,etal.HSP90InhibitionDrivesDegradationofFGFR2FusionProteins:ImplicationsforTreatmentofCholangiocarcinoma[J].WANGM,SHENA,ZHANGC,etal.DevelopmentofHeatShockP(Hsp90)InhibitorsToCombatResistacetoTyrosineKinaseInhibitorsthroughHsp90–KinaseInteractions[J].JMedChem,2016,59(12):5563-55Cholangiocarcinoma.NatRevDisPrimers7,66(2021).1038/s41572-021-00305-中国抗癌协会肝癌专业委员会胆管癌协作组.原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J].中华消化外科杂志,2022,21(10):1269-1301ZHUAX,MEYERHARDTJA,BLASZKOWSKYLS,etal.Efficacyandsafetyofgemcitabine,oxaliplatin,andbevacizumabinadvancedbiliary-tractcancersandcorrelationofchangesin18-fluorodeoxyglucosePETwithclinicaloutcome:aphase2study[J].LancetOncol,2010,11(1):48-54LUBNERSJ,MAHONEYMR,KOLESARJL,etal.ReportofamulticenterphaseIItrialtestingacombinationofbiweeklybevacizumabanddailyerlotinibinpatientswithunresectablebiliarycancer:aphaseIIConsortiumstudy[J].JClinOncol,2010,28(21):3491-3497申建刚,张定国,朱惠明.血管内皮生长因子-AsiR-NA对人肝癌HepG2细胞凋亡的影响及机SongJ,GuanZ,SongC,etal.Apatinibsuppressesthemigration,invasionandangiogenesisofhepatocellu-larcarcinomacellsbyblockingVEGFandPI3K/AKTsignalingpathways［J］.MolMedRep,2021,23(6):429GrassianAR,PagliariniR,ChiangDY.Mutationsofisocitratedehydrogenase1and2inintrahepaticcholangiocarcinoma[J].CurrOpinGastroenterol,2014(3):295-302CasakSJ,PradhanSFashoyin-AjeLA,etalFDAApprovalSummary:Ivosidenibforthetreatmentofpatientswithadvancedunresectableormetastatic,chemotherapyrefractorycholangiocarcinomawithanIDH1mutation[J].ClinCancerRes,2022,28(13):2733-2737、\hJohnNeilPrimroseetal.,Adjuvantcapecitabineforbiliarytractcancer:TheBILCAPrandomizedstudy.JCO35,4006-4006(2017)..[J].中国医学创新，2023，20（18）：1-LEIZ,MAW,SIA,etal.EffectofdifferentPD-1inhibitorcombinationtherapiesforunresectableintrahepaticcholangiocarcinoma[J].AlimentPharmacolTher,2023,58(6):611-622.DOI:ZHUSG,LIHB,DAITX,etal.SuccessfultreatmentofstageIIIBintrahepaticcholangiocarcinomausingneoadjuvanttherapywiththePD-1inhibitorcamrelizumab:acasereport[J].WorldJClinCases,2022,10(27):9743-9749.DOI:10.12998/wjcc.v10.i27.9743ZHANGT,CHENJ,NIUL,etal.Clinicalsafetyandefficac